tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ohye H et al. Effects of immunosuppressant agents on growth hormone release and gene expression. 1998 Endocr. J. pmid:9790238
Casavilla FA et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. 1998 Liver Transpl Surg pmid:9791154
Toshima K et al. Effect of FK506 on the activation state of hepatic macrophages in Propionibacterium acnes-treated rats. 1998 J. Gastroenterol. Hepatol. pmid:9792034
Sengoku T et al. [Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice]. 1998 Nippon Yakurigaku Zasshi pmid:9793077
Hashimoto Y et al. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. 1998 Pharm. Res. pmid:9794505
Kobayashi M et al. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. 1998 Nephrol. Dial. Transplant. pmid:9794552
Schaefer A et al. Stimulation of the Ca2+-mediated egr-1 and c-fos expression in murine erythroleukaemia cells by cyclosporin A. 1998 Biochem. J. pmid:9794788
Whitcup SM et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. 1998 Ocul. Immunol. Inflamm. pmid:9798194
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Garcia-Criado FJ et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. 1998 Transplantation pmid:9798713
Fisher NC Renal failure after lung transplantation. 1998 Lancet pmid:9800782
Conti F et al. Low level of interleukin 10 synthesis during liver allograft rejection. 1998 Lab. Invest. pmid:9800954
Reis A et al. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. 1998 Graefes Arch. Clin. Exp. Ophthalmol. pmid:9801895
Bieber T Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. 1998 J. Allergy Clin. Immunol. pmid:9802361
Boguniewicz M et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. 1998 J. Allergy Clin. Immunol. pmid:9802373
Faure JD et al. An Arabidopsis immunophilin, AtFKBP12, binds to AtFIP37 (FKBP interacting protein) in an interaction that is disrupted by FK506. 1998 Plant J. pmid:9807817
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Hultsch T et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. 1998 Arch. Dermatol. Res. pmid:9808344
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Marton MJ et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. 1998 Nat. Med. pmid:9809554
Walder B et al. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. 1998 J. Heart Lung Transplant. pmid:9811409
Bachinger A et al. [Immunosuppression with tacrolimus (FK 506) and cyclosporin A for preventing graft rejection after liver transplantation. Retrospective evaluation of medical costs based on the FG-O157 Study in 224 patients (Germany)]. 1998 Chirurg pmid:9816454
Shapiro R et al. A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. 1998 J. Urol. pmid:9817305
Wells WA Coming full circle. Vertex Pharmaceuticals, Inc. 1998 Chem. Biol. pmid:9818152
Ader JL and Rostaing L Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506. 1998 Curr. Opin. Nephrol. Hypertens. pmid:9818201
Perego C et al. Evidence that SMS 201-995 enhances the immunosuppressive effect of FK506. 1998 Int. J. Immunopharmacol. pmid:9818792
Campo JV et al. Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. 1998 Arch. Gen. Psychiatry pmid:9819077
Igarashi K et al. A novel indication of the activities of small molecule inhibitors of protein-protein interactions: application of the yeast two-hybrid system. 1998 J. Antibiot. pmid:9820241
Neylan JF et al. Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. 1998 Am. J. Kidney Dis. pmid:9820446
Patella V et al. Endogenous superallergen protein Fv induces IL-4 secretion from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. 1998 J. Immunol. pmid:9820545
Rossi FM and Blau HM Recent advances in inducible gene expression systems. 1998 Curr. Opin. Biotechnol. pmid:9821271
Antoni FA et al. Ca2+/calcineurin-inhibited adenylyl cyclase, highly abundant in forebrain regions, is important for learning and memory. 1998 J. Neurosci. pmid:9822726
Maghrabi K and Bohlega S Cyclosporine-induced migraine with severe vomiting causing loss of renal graft. 1998 Clin Neurol Neurosurg pmid:9822847
Mitsuhashi H et al. Sulfite is released by human neutrophils in response to stimulation with lipopolysaccharide. 1998 J. Leukoc. Biol. pmid:9823763
Papatheodoridis GV et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. 1998 Gut pmid:9824344
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Jain AB et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. 1998 Transplantation pmid:9825817
Franz M et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? 1998 Transplantation pmid:9825827
Basile C et al. Tacrolimus and gingival hyperplasia. 1998 Nephrol. Dial. Transplant. pmid:9829526
Fehrman-Ekholm I and Nisell H A successful pregnancy in a kidney recipient with tacrolimus (Prograf, FK 506) therapy. 1998 Nephrol. Dial. Transplant. pmid:9829528
Armstrong VW et al. Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography-tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). 1998 Clin. Chem. pmid:9836720
Carver LA et al. Characterization of the Ah receptor-associated protein, ARA9. 1998 J. Biol. Chem. pmid:9837941
Takahashi N et al. Nitric oxide generation in renal allograft recipients. 1998 Transplant. Proc. pmid:9838306
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Ramirez CB et al. Early steroid withdrawal after liver transplantation. 1998 Transplant. Proc. pmid:9838406
Ko WJ et al. Clinical trial of FK506 in heart transplant patients in Taiwan: report of 7 cases with immunosuppression switch from cyclosporine to FK506. 1998 Transplant. Proc. pmid:9838474
Sasaki K et al. Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. 1998 Transplant. Proc. pmid:9838521
Takayama J et al. Living related liver transplantation in patients with ABO incompatibility. 1998 Transplant. Proc. pmid:9838537
Wu MS et al. Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. 1998 Transplant. Proc. pmid:9838561
Shu KH et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. 1998 Transplant. Proc. pmid:9838570
Lo CM et al. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. 1998 Transplant. Proc. pmid:9838571
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Cheng HM et al. Primary prophylaxis with tacrolimus in kidney transplants in China. 1998 Transplant. Proc. pmid:9838573
Goh BL et al. FK506 rescue therapy for acute renal allograft rejection. 1998 Transplant. Proc. pmid:9838574
Goh BL and Tan SY FK506 "rescue" therapy complicated by renal tubular acidosis in renal allograft recipients. 1998 Transplant. Proc. pmid:9838575
Jeong HJ et al. Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats. 1998 Transplant. Proc. pmid:9838576
Yura H et al. Development of a macromolecular prodrug of FK506: I. Synthesis of FK506-dextran conjugate. 1998 Transplant. Proc. pmid:9838577
Yamauchi M et al. Effects of FK506 on rat thymic microenvironment in thymocyte maturation, proliferation, and mobilization. 1998 Transplant. Proc. pmid:9838578
Watanabe K et al. Prolongation effect of FK506 on the survival of 3-day preserved kidney allografts in dogs. 1998 Transplant. Proc. pmid:9838579
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Watanabe Y et al. Enteric absorption of FK 506: estimation by a block liver perfusion technique in rats. 1998 Transplant. Proc. pmid:9838656
Hattori R et al. FK 506 in cadaveric kidney transplantation from non-heart-beating donors. 1998 Transplant. Proc. pmid:9838666
Takeda M et al. Immunologic factors contributing to acute rejection in lungs xenotransplanted between primates. 1998 Transplant. Proc. pmid:9838670
Fukushima N et al. Prolonged survival of pig cardiac xenografts in baboons by sequential cardiac transplantation. 1998 Transplant. Proc. pmid:9838671
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Sanada O et al. Establishment of chimerism in donors by intraportal injection of recipient-type bone marrow cells with concomitant administration of FK 506 before liver transplantation prolongs liver allograft survival in rats. 1998 Transplant. Proc. pmid:9838689
Sho M et al. Simultaneous inoculation of donor lymphocyte subsets with transplantation in a rat cardiac allograft model. 1998 Transplant. Proc. pmid:9838696
Navarro-Antolín J et al. CsA and FK506 up-regulate eNOS expression: role of reactive oxygen species and AP-1. 1998 Kidney Int. Suppl. pmid:9839278
del Castillo D et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. 1998 Kidney Int. Suppl. pmid:9839298
Kass L et al. Inhibition of the calcineurin-like protein phosphatase activity in Limulus ventral eye photoreceptor cells alters the characteristics of the spontaneous quantal bumps and the light-mediated inward currents, and enhances arrestin phosphorylation. 1998 Nov-Dec Vis. Neurosci. pmid:9839968
Hayashi M et al. Characterization of allograft rejection in an experimental model of small intestinal transplantation. 1998 Jul-Aug J. Gastrointest. Surg. pmid:9841989
Wallemacq PE et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. 1998 Jul-Sep Eur J Drug Metab Pharmacokinet pmid:9842978
duBell WH et al. Independent inhibition of calcineurin and K+ currents by the immunosuppressant FK-506 in rat ventricle. 1998 Am. J. Physiol. pmid:9843803
Aoki Y et al. CsA-sensitive purine-box transcriptional regulator in bronchial epithelial cells contains NF45, NF90, and Ku. 1998 Am. J. Physiol. pmid:9843854
Haug C et al. Endothelin release by rabbit proximal tubule cells: modulatory effects of cyclosporine A, tacrolimus, HGF and EGF. 1998 Kidney Int. pmid:9844139
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Sohn HW et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells. 1998 Am. J. Pathol. pmid:9846983
Reddy RK et al. High-molecular-weight FK506-binding proteins are components of heat-shock protein 90 heterocomplexes in wheat germ lysate. 1998 Plant Physiol. pmid:9847114
Laskow DA et al. The role of tacrolimus in adult kidney transplantation: a review. 1998 Clin Transplant pmid:9850440
Nishida S et al. Allograft rejection of small bowel transplantation in pigs. 1998 Surg. Today pmid:9851621
Gammie JS et al. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts. 1998 Circulation pmid:9852899
Pou L et al. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. 1998 Ther Drug Monit pmid:9853973
Brunet M et al. Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation. 1998 Ther Drug Monit pmid:9853987
Hatori M et al. Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year. 1998 Int. J. Urol. pmid:9855119
Olyaei AJ et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. 1998 Nov-Dec Pharmacotherapy pmid:9855339
Hamilton GS and Steiner JP Immunophilins: beyond immunosuppression. 1998 J. Med. Chem. pmid:9857082
Paul C and Ho VC Ascomycins in dermatology. 1998 Semin Cutan Med Surg pmid:9859912
Shapiro VS et al. Nuclear factor of activated T cells and AP-1 are insufficient for IL-2 promoter activation: requirement for CD28 up-regulation of RE/AP. 1998 J. Immunol. pmid:9862666
Maggi U et al. Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation. 1998 Transplant. Proc. pmid:9865255
Opelz G Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study. 1998 Transplant. Proc. pmid:9865286
Moffatt SD et al. Comparative efficacy of liposomal FK506 with FK506. 1998 Transplant. Proc. pmid:9865297
Brunet M et al. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. 1998 Transplant. Proc. pmid:9865298
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
du Toit DF et al. Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. 1998 Transplant. Proc. pmid:9865300
Daoud AJ et al. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. 1998 Transplant. Proc. pmid:9865303
Braun F et al. How to handle mycophenolate mofetil in combination with tacrolimus? 1998 Transplant. Proc. pmid:9865309
Schorlemmer HU et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. 1998 Transplant. Proc. pmid:9865312
Metcalfe SM et al. In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. 1998 Transplant. Proc. pmid:9865315